China’s NMPA approves Novartis’ Cosentyx and Merck’s Keytruda

China’s NMPA approves two drugs: Novartis’ IL-17A Cosentyx for plaque psoriasis and Merck’s anit-PD-1 Keytruda for NSCLC. Credit: Pixabay.



  • China's NMPA approves two drugs